Abu Dhabi Leads AstraZeneca and Oracle AI Collaboration
··1 min read
Abu Dhabi, UAE, 2023. AstraZeneca has announced a collaboration with Oracle to enhance clinical research using artificial intelligence (AI) and real-world data.
The partnership, led from Abu Dhabi, aims to improve patient identification for clinical trials and safety monitoring. AstraZeneca will utilize Oracle's AI and data capabilities to analyze vast amounts of real-world data, enabling more precise and efficient patient selection for clinical research.
This collaboration is part of AstraZeneca's broader effort to advance clinical research. The initiative will focus on identifying patients suitable for clinical trials and monitoring safety indicators.
The project will leverage Oracle's advanced AI and data analytics tools to process and analyze real-world data, enhancing the accuracy and efficiency of patient identification and safety monitoring in clinical trials.
By integrating AI and real-world data, AstraZeneca and Oracle aim to streamline clinical research processes, reduce costs, and accelerate the development of new treatments.
This collaboration underscores the growing importance of AI and data analytics in the pharmaceutical industry, as companies seek to improve the efficiency and effectiveness of clinical research.
CONTEXT: This collaboration is significant as it highlights the increasing role of AI and real-world data in improving clinical research processes, which could lead to faster and more accurate drug development.
